A Phase 3 interventional study of Rosuvastatin 5mg and DP-R207 5/10mg in Primary Hypercholesterolemia, sponsored by Alvogen Korea. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2015-05-15.
Sponsored by Alvogen Korea (part of Lotus Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 24th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2014, is one of 33 in phase 3, and was the 44th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 379 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 203 across the 57 interventional studies. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 59 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alvogen Korea, one of the names counted as Lotus Pharmaceutical Co., Ltd.. Under that name alone:
Alvogen Korea is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Lotus Pharmaceutical Co., Ltd. has 2 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate efficacy and safety of DP-R207 in patients with primary hypercholesterolemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once a day, administration of rosuvastatin 5mg and two types of placebo for 20 weeks
Drug: Rosuvastatin 5mg · Drug: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg) · Drug: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)
Once a day, administration of DP-R207 5/10mg and two types of placebo for 20 weeks
Drug: DP-R207 5/10mg · Drug: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg) · Drug: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)
Once a day, administration of rosuvastatin 10mg and two types of placebo for 20 weeks
Drug: Rosuvastatin 10mg · Drug: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg) · Drug: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)
Once a day, administration of DP-R207 10/10mg and two types of placebo for 20 weeks
Drug: DP-R207 10/10mg · Drug: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg) · Drug: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)
Once a day, administration of rosuvastatin 20mg and two types of placebo for 20 weeks
Drug: Rosuvastatin 20mg · Drug: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg) · Drug: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)
Once a day, administration of DP-R207 20/10mg and two types of placebo for 20 weeks
Drug: DP-R207 20/10mg · Drug: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg) · Drug: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)
Drug page: Rosuvastatin
Also known as: Rosuvastatin 5mg, Ezetimibe 10mg
Drug page: Rosuvastatin
Also known as: Rosuvastatin 10mg, Ezetimibe 10mg
Drug page: Rosuvastatin
Also known as: Rosuvastatin 20mg, Ezetimibe 10mg
Percent change from baseline to 8 weeks in LDL-Cholesterol
Time frame: baseline and 8 weeks
Percent change from baseline to 4 weeks in LDL-Cholesterol
Time frame: baseline and 4 weeks
Percent change from baseline to 4 weeks in lipid related blood test results
Time frame: baseline and 4 weeks
Percent change from baseline to 8 weeks in lipid related blood test results
Time frame: baseline and 8 weeks
Percentage of patients reaching treatment goals according to NCEP ATP III Guideline
Time frame: week 4 and week 8
The record gives a start of Jul 2014, a primary completion of Jan 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin